Camara, Mahamadou D.
Zhou, Yitian
De Sousa, Taís Nóbrega
Gil, José P.
Djimde, Abdoulaye A.
Lauschke, Volker M.
Funding for this research was provided by:
South African Medical Research Council (3000038516, 3000038516)
Cancerfonden (23-0763PT)
European and Developing Countries Clinical Trials Partnership (RIA2017T-2018, RIA2017T-2018)
Vetenskapsrådet (2021-02801)
Karolinska Institute
Article History
Received: 1 April 2024
Accepted: 16 April 2024
First Online: 22 April 2024
Declarations
:
: V.M.L. is co-founder, CEO and shareholder of HepaPredict AB. Y.Z. and V.M.L. are co-founders and shareholders of Shanghai Hepo Biotechnology Ltd. The other authors declare no competing interests.